Crossmark

Comment on real-world persistence and interpretation of BMD outcomes in denosumab vs. alendronate therapy

Crossref DOI link: https://doi.org/10.1007/s00774-026-01694-3

Published Online: 2026-01-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mori, Yu https://orcid.org/0000-0002-8225-4690
Mori, Naoko
License Information

Text and Data Mining valid from 2026-01-22

Version of Record valid from 2026-01-22
More Information

Article History

Received: 23 November 2025

Accepted: 2 January 2026

First Online: 22 January 2026

Declarations

:

: The authors declare no conflicts of interest associated with this manuscript.